
|Videos|August 22, 2022
Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC
Author(s)Urology Times staff
Advertisement
Vignesh Packiam, MD, explains the background of the study, “Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer,” which was published in the Journal of Urology. Packiam is a clinical assistant professor of Urology, Department of Urology, University of Iowa Hospitals and Clinics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC
5






